Cantor Fitzgerald, L. P. Compass Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $8.4 Billion
- Q3 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 80,000 shares of CMPX stock, worth $390,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80,000
Previous 80,000
-0.0%
Holding current value
$390,400
Previous $300,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CMPX
# of Institutions
126Shares Held
143MCall Options Held
1.02MPut Options Held
0-
Tang Capital Management LLC San Diego, CA16.8MShares$82 Million2.87% of portfolio
-
Orbimed Advisors LLC San Diego, CA15.2MShares$74.3 Million1.95% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.1MShares$68.8 Million1.59% of portfolio
-
Blackstone Inc New York, NY9.84MShares$48 Million0.17% of portfolio
-
Vivo Capital, LLC Palo Alto, CA9.55MShares$46.6 Million5.69% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $494M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...